Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 03, 2023 05:00 ET | Source: Alvotech

Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)

REYKJAVIK, Iceland and PISCATAWAY, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
September 25, 2023 04:00 ET | Source: Alvotech

Markaðsleyfi veitt í Japan fyrir AVT04 (ustekinumab), líftæknilyfjahliðstæðu Alvotech við Stelara®

Alvotech (NASDAQ: ALVO) tilkynnti í dag að japanska heilbrigðis-, atvinnu- og velferðarráðuneytið hafi veitt Fuji Pharma Co. Ltd. („Fuji“), samstarfsaðila Alvotech í Japan, leyfi til markaðssetningar-...
September 25, 2023 04:00 ET | Source: Alvotech

Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in...
September 25, 2023 04:00 ET | Source: Alvotech

Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®

REYKJAVIK, Iceland, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
September 20, 2023 04:30 ET | Source: Alvotech

Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food...
September 20, 2023 04:30 ET | Source: Alvotech

Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT02 (adalimumab) í Bandaríkjunum

Alvotech (NASDAQ: ALVO) tilkynnti í dag að Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) hefði staðfest að umsókn Alvotech um markaðsleyfi fyrir AVT02 sem lögð hefur verið fram að nýju hafi verið...
September 20, 2023 04:30 ET | Source: Alvotech

Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)

REYKJAVIK, Iceland, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
September 11, 2023 05:00 ET | Source: Alvotech

Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 21st...
September 11, 2023 05:00 ET | Source: Alvotech

Alvotech tekur þátt í 21. heilbrigðisráðstefnu Morgans Stanleys

Alvotech (NASDAQ: ALVO) tekur þátt í árlegri heilbrigðisráðstefnu fjárfestingabankans Morgans Stanleys sem haldin verður í tuttugasta og fyrsta sinn í New York dagana 11.-13. september nk. Ming...
September 05, 2023 09:30 ET | Source: Alvotech

Alvotech Announces Changes to the Leadership Team

Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Faysal Kalmoua has...